
PRCT Stock Forecast & Price Target
PRCT Analyst Ratings
Bulls say
PROCEPT BioRobotics Corp has demonstrated a consistent average growth of approximately 6.1% per quarter in handpiece utilization over the past six quarters, indicating a robust increase in the adoption of its surgical systems. In early 2024, the company strategically focused on curtailing operating expenses to grow at half the pace of top-line growth, signaling a commitment to achieving profitability amidst market challenges. Additionally, management expressed confidence in the strong visibility of its pipeline and reported 58 new system placements in the most recent quarter, surpassing their previous guidance and suggesting a positive trajectory for future revenue growth.
Bears say
PROCEPT BioRobotics has experienced a significant decline in its stock price, down approximately 54% year-to-date, indicating a challenging financial landscape despite the company's ability to exceed its own guidance. Key factors contributing to a negative outlook include potential declines in capital equipment demand, reduced usage of handpieces by customers, and increased competitive pressures, alongside concerns regarding changes in reimbursement for its Aquablation therapy. The anticipated consensus for future sales in 2026 may also see downward adjustments as investors react to these ongoing concerns regarding utilization and inventory levels.
This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.
PRCT Analyst Forecast & Price Prediction
Start investing in PRCT
Order type
Buy in
Order amount
Est. shares
0 shares